The Arkansas Integrative Metabolic Research Center (AIMRC) will host Dr. Kevin Murach, an associate professor of exercise, at 12:55 p.m. on Wednesday, April 29, in CHEM 0144.
Neuroblastoma can be a particularly insidious cancer. In about half of all cases, tumors regress, even without therapy. In the other half, tumors grow very quickly. These tumors often respond well to ...
Efforts to develop effective therapies for MYC-amplified Group 3 medulloblastoma (G3-MB) are hindered by an incomplete ...
Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...
ctDNA clearance within 10 weeks of TKI treatment initiation correlates with improved OS and PFS in advanced NSCLC patients. ctDNA is emerging as a promising early biomarker for predicting clinical ...
From marathon fundraising to laboratory discovery, Oncogene Cancer Research continues to support work that brings patients ...
Analysis of thromboembolic events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A single-center real-world study. This is an ASCO Meeting Abstract from the ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results